Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 Marktech Optoelectronics ... deep ultra violet emitters in the 280 nm wavelength ... UV emitters which range from 280nm to 405nm. These ... water sanitation as well as curing. Mark Campito, Marktech’s ... of special interest to manufacturers is that we offer ...
(Date:9/23/2014)... September 23, 2014 The Minnesota ... developer of cellular modems , platforms and ... the Startup category for the 2014 Tekne Awards. ... at the Minneapolis Convention Center on Thursday, November ... individuals who have shown superior technology innovation and ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... , Chemosaturation Demonstrates Clinically Meaningful Tumor ... Delcath Systems, Inc. (NASDAQ: DCTH ... tumor (mNET) cohort of the Company,s recently completed Phase ... and Interventional Radiological Society of Europe (CIRSE) congress ...
... N.Y. A new system to be installed ... enable exciting new research possibilities across the nation ... modeling and simulation, data science, high-performance computing, and ... million grant from the National Science Foundation (NSF) ...
... All ABC Members and Members of the Herb and ... that I inform you of the passing of our ... Saturday evening, September 10, per the tribute we have ... Director, American Botanical Council, Editor, HerbalGram & HerbClip ...
Cached Biology Technology:Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 3Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 4Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 5New supercomputer to boost Rensselaer leadership in high-performance computing 2New supercomputer to boost Rensselaer leadership in high-performance computing 3New supercomputer to boost Rensselaer leadership in high-performance computing 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 2Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 3Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 5Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 6Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 7
(Date:9/23/2014)... fragments called "jumping genes" that insert themselves into DNA ... phenomenon can result in age-related diseases such as cancer. ... that the "jumping genes" in mice become active as ... them in check in order to take on another ... Nature Communications , Professor of Biology Vera Gorbunova ...
(Date:9/22/2014)... new American Cancer Society study suggests that participants ... known as the food stamp program, had lower ... The authors say the findings emphasize the need ... quality of SNAP participants. , The SNAP program ... the resources to obtain a nutritionally adequate diet. ...
(Date:9/22/2014)... researchers are studying a potential new treatment that reverses ... which scars develop in the lungs and severely hamper ... which is delivered to lung tissue intravenously. In mouse ... fibrosis after several days. , The findings were ... Medicine . , "The mimic, when injected into the ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2
... the Upper Paraguay River and its tributaries, is the largest ... of organisms and it is an ark for large populations ... Pantanal fulfills a large range of ecosystem services that are ... seasonal floodplain system, plants, animals, and local human populations show ...
... cover all from the historical aspects of the beaver ... the development of reintroduced or recovering populations, consequences of ... beavers, relationship with animal and plant communities on land ... the high degree to which the beaver is able ...
... (Nicols Prez Hidalgo and M. Pilar Mier Durante) have ... Matsumura ) in Madrid, Spain from a photography displayed ... ) (ngel Umaran). The results have been published recently ... are available for free download. "This discovery is ...
Cached Biology News:
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
...
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
... Staccato Series of systems provide fast and ... , genomics, proteomics and drug development laboratories. ... configurations; Mini Workstation Series, Application Series and ... Station is a remarkably compact system for ...
Biology Products: